TY  - GEN
AU  - Judge, Daniel P
AU  - Gillmore, Julian D
AU  - Alexander, Kevin M
AU  - Ambardekar, Amrut V
AU  - Cappelli, Francesco
AU  - Fontana, Marianna
AU  - García-Pavía, Pablo
AU  - Grodin, Justin L
AU  - Grogan, Martha
AU  - Hanna, Mazen
AU  - Masri, Ahmad
AU  - Nativi-Nicolau, Jose
AU  - Obici, Laura
AU  - Hvitfeldt Poulsen, Steen
AU  - Sarswat, Nitasha
AU  - Shah, Keyur
AU  - Soman, Prem
AU  - Lystig, Ted
AU  - Cao, Xiaofan
AU  - Wang, Kevin
AU  - Pecoraro, Maria Lucia
AU  - Tamby, Jean-François
AU  - Katz, Leonid
AU  - Sinha, Uma
AU  - Fox, Jonathan C
AU  - Maurer, Mathew S
PY  - 2025
UR  - https://hdl.handle.net/20.500.12105/26828
AB  - In the phase 3 randomized controlled study ATTRibute-CM (Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy), acoramidis, a transthyretin stabilizer, demonstrated significant efficacy on the primary end point....
LA  - eng
PB  - LIPPINCOTT WILLIAMS & WILKINS
KW  - amyloidosis, familial
KW  - clinical trials as topic
KW  - exercise tolerance
KW  - hospitalization
KW  - mortality
KW  - quality of life
KW  - transthyretin-related heart failure
TI  - Long-Term Efficacy and Safety of Acoramidis in ATTR-CM: Initial Report From the Open-Label Extension of the ATTRibute-CM Trial.
TY  - research article
ER  -